Sauriol, Skye Alexandre
Carmona, Euridice
Udaskin, Molly L.
Radulovich, Nikolina
Leclerc-Desaulniers, Kim
Rottapel, Robert
Oza, Amit M.
Lheureux, Stephanie
Provencher, Diane M.
Mes-Masson, Anne-Marie
Funding for this research was provided by:
Oncopole in collaboration with the FRQS, the Cancer Research Society, Génome Québec and IRICoR (265877)
Article History
Received: 28 November 2022
Accepted: 15 February 2023
First Online: 27 February 2023
Change Date: 1 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-60769-1
Competing interests
: SL receives honoraria from GlaxoSmithKline, AstraZeneca, Roche, and Merck, and is principal and co-investigator for various PARP inhibitor treatments. The other authors declare no potential conflicts of interest.